Date: 2016-03-07
Type of information: Services contract
Compound: lentiviral vector-based products
Company: Oxford BioMedica (UK) Immune Design Corp (USA)
Therapeutic area: Cancer - Oncology
Type agreement: services contract
Action mechanism: gene therapy
Disease: cancer, chronic diseases
Details: * On September 27, 2012, Oxford BioMedica, a UK gene-based biopharmaceutical company, has signed a master services agreement with Immune Design, a privately held biotechnology company based in Seattle, Washington (USA), which is developing a therapeutic vaccine utilising a lentiviral-based vector in order to target cancer and other chronic diseases. The collaboration aims to leverage Oxford BioMedica’s expertise in lentiviral vector clinical development by focusing on the design and validation of custom analytical methods, in order to facilitate the future clinical development path for Immune Design’s pre-clinical therapeutic vaccine candidate for the treatment of cancer.
Financial terms:
Latest news: * On March 7, 2016, Oxford BioMedica announced a new and expanded collaboration with Immune Design, a clinical-stage immunotherapy company focused in oncology, as well as a non-exclusive, royalty-bearing, intellectual property licence to Immune Design. The licence involves the use of lentiviral vector-based products for the in vivo treatment or prevention of cancer. The collaboration builds on Immune Design’s earlier process development collaboration with the Group, signed in 2012, which covered the development of analytic assays. Financial and other terms have not been disclosed.
